A Randomized, Open-Label, Phase 3 Trial of Pembrolizumab Plus Epacadostat Versus Sunitinib or Pazopanib As First-Line Treatment for Metastatic Renal Cell Carcinoma (KEYNOTE-679/ECHO-302)
BMC Cancer（2024）
Key words
Renal cell carcinoma,Programmed death 1,PD-1,Indoleamine 2,3-deoxygenase 1,IDO1,Pembrolizumab,Epacadostat
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined